BCG047
/ Biocytogen
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
BCG047, a novel heavy chain antibody-drug conjugate targeting FOLR1, demonstrates outstanding preclinical antitumor efficacy
(AACR 2026)
- "Abstract is embargoed at this time."
ADC • Late-breaking abstract • Preclinical • Oncology • FOLR1
1 to 1
Of
1
Go to page
1